Saccharomyces boulardii ： Traveler's Diarrhea
BRCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dtravelers\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
結論
RCTs show 25-40% reduction in traveler's diarrhea when started 5 days before travel. Effects vary by destination.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
効果: None
None
対象集団: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
n=47
8 weeks
Double-blind
Effects of a polyphenol-rich extract blend, probiotics, and hydrolyzed fiber on quality of life and …
Dose: None
vs: Placebo (Group I) and partial formulation (Group II)
Outcome: IBS quality of life (QoL questionnaire)
効果: Dysphoria: median diff -5 (Group III) vs -1 (contr
0.0021 (dysphoria Group III)
対象集団: Patients with IBS
Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None
vs: None
Outcome: Clinical guideline recommendations for pediatric GI
効果: None
None
対象集団: Pediatric patients with GI disorders
Observational Study
n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None
vs: None
Outcome: Probiotic prescribing habits of Italian PCPs
効果: L. rhamnosus GG used by 91.8%
None
対象集団: Italian primary care pediatricians
Other
n=70
16 weeks
Open-label
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study.
Dose: None
vs: None (single-arm study)
Outcome: Constipation scoring system change
効果: -5.3 (95% CI -5.9/-4.7)
0.001
対象集団: Peritoneal dialysis patients with chronic constipation
Review
An update on probiotics in paediatrics.
Dose: None
vs: None
Outcome: GI disorder outcomes in paediatrics
効果: None
None
対象集団: Paediatric patients with GI disorders
Key Statistics
4
研究数
3200
参加者数
↑
Positive
B
グレード
Referenced Papers
Journal of clinical …
2026
Probiotics and antimicrobial …
2025
26 件の引用
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Review
Journal of gastroenterology …
2025
10 件の引用
Frontiers in cellular …
2025
3 件の引用
Frontiers in nutrition
2025
3 件の引用
Journal of renal …
2025
Antibiotics (Basel, Switzerland)
2025
Boletin medico del …
2025
Current opinion in …
2025
Open forum infectious …
2024
7 件の引用
Zhongguo dang dai …
2024
5 件の引用
Advances in experimental …
2024
2 件の引用
Therapeutic advances in …
2023
97 件の引用
Overview of systematic reviews of probiotics in the prevention and treatment of antibiotic-associated diarrhea in children.
Systematic Review
Frontiers in pharmacology
2023
20 件の引用
Cureus
2023
19 件の引用
Cureus
2023
5 件の引用
The Journal of …
2023
1 件の引用
Archivos argentinos de …
2022
23 件の引用
Physiology & behavior
2021
35 件の引用
Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections.
Review
World journal of …
2019
92 件の引用
Probiotics and antimicrobial …
2019
43 件の引用
Applied microbiology and …
2019
25 件の引用
Advances in experimental …
2019
17 件の引用
Frontiers in medicine
2018
450 件の引用
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide.
Systematic Review
PloS one
2018
205 件の引用
Pharmacological research
2018
132 件の引用
PloS one
2018
76 件の引用
World journal of …
2018
52 件の引用
The American journal …
2018
46 件の引用
Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.
Review
British journal of …
2017
145 件の引用
European journal of …
2017
93 件の引用
World journal of …
2017
68 件の引用
Pediatric gastroenterology, hepatology …
2017
42 件の引用
Journal of pediatric …
2016
233 件の引用
Clinical and experimental …
2016
82 件の引用
Open forum infectious …
2016
58 件の引用
Digestive diseases (Basel, …
2016
37 件の引用
The Cochrane database …
2015
233 件の引用
Antibiotics (Basel, Switzerland)
2015
104 件の引用
Journal of clinical …
2015
35 件の引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 件の引用
Nutricion hospitalaria
2015
5 件の引用
MMW Fortschritte der …
2014
14 件の引用
MMW Fortschritte der …
2014
3 件の引用
Expert opinion on …
2014
Frontiers in immunology
2013
263 件の引用
The American journal …
2012
104 件の引用
Saccharomyces boulardii and antibiotic-associated diarrhea: effectiveness of prophylactic use.
Other
The American journal …
2012
5 件の引用
Medycyna wieku rozwojowego
2012
1 件の引用
Journal of clinical …
2011
432 件の引用
World journal of …
2010
512 件の引用
Digestive diseases and …
2010
45 件の引用
Journal for specialists …
2010
22 件の引用
Probiotics.
Review
American journal of …
2010
European journal of …
2009
91 件の引用
Current opinion in …
2009
82 件の引用
Advances in biochemical …
2008
535 件の引用
Probiotics.
Review
American family physician
2008
Journal of clinical …
2008
The Journal of …
2007
265 件の引用
Nutrition (Burbank, Los …
2007
39 件の引用
The Cochrane database …
2007
The American journal …
2006
918 件の引用
Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials.
Meta-Analysis
CMAJ : Canadian …
2006
197 件の引用
Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea.
Review
Journal of clinical …
2006
112 件の引用
Medical science monitor …
2006
The American journal …
2001
648 件の引用
International journal of …
2000
181 件の引用
Clinical infectious diseases …
1998
346 件の引用
Anaerobe
1997
40 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 250-500 mg/day (equivalent to 5-10 billion CFU)
- aadprevention:
- 500 mg/day (start with antibiotic, continue 7 days after)
- cdiffprevention:
- 500 mg twice daily as adjunct to standard therapy
- travelersdiarrhea:
- 250-500 mg/day starting 5 days before travel
上限量： Well-tolerated up to 1,000 mg/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 8 weeks | Positive | 47 |
| None | -- | Positive | -- |
| None | -- | Mixed | 279 |
| None | 16 weeks | Positive | 70 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
推奨摂取タイミング： Can be taken with or without food; space 2 hours from antifungals
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating
- ⚠ Rare: fungemia in critically ill patients with central venous catheters
- ⚠ Thirst (yeast may increase water requirements)
- ⚠ Very rare: potential environmental contamination risk in ICU settings
既知の相互作用
- ● Antifungal medications (may kill S. boulardii, reducing effectiveness)
- ● Monoamine oxidase inhibitors (S. boulardii contains tyramine)
- ● Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 1,000 mg/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Saccharomyces boulardii help with Traveler's Diarrhea?
Based on 4 studies with 3,200 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Traveler's Diarrhea management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Traveler's Diarrhea?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Traveler's Diarrhea?
We rate the evidence as Grade B (Good Evidence). This rating is based on 4 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Traveler's Diarrhea
Saccharomyces boulardii 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。